REPLY TO ADRION ET AL. ON PATEL ET AL. Letter to the Editor, British Medical Journal

Patel, M., Arshad, Q., Seemungal, B.M., Harcourt, J.P., Golding, J.F. and Bronstein, A.M. 2018. REPLY TO ADRION ET AL. ON PATEL ET AL. Letter to the Editor, British Medical Journal . British Medical Journal.

TitleREPLY TO ADRION ET AL. ON PATEL ET AL. Letter to the Editor, British Medical Journal
AuthorsPatel, M., Arshad, Q., Seemungal, B.M., Harcourt, J.P., Golding, J.F. and Bronstein, A.M.
Abstract

We apologise for not having noticed earlier Adrion and colleagues’ comments on our study comparing the effectiveness of intratympanic Methylprednisolone to Gentamicin in refractory Ménière’s disease [1], covered by the BMJ [2]. Contrary to our expectations, both drugs were equally effective in controlling vertigo (primary outcome).
Adrion’s main concerns were, (i) that negative studies pose the problem of “not knowing how to interpret the non-significant results in a clinically relevant way” and, (ii) the lack of a power calculation for the primary outcome.
Regarding (i), our interpretation is that given the known ototoxic effects of gentamicin, ascertaining any minuscule difference between the two drugs is not justified and, very likely, unethical. A further comment was that “transforming the data to achieve a more symmetric distribution may have resulted in more power when an ANOVA or t-test is applied”. We agree that some of the data deviated from strict normality. There is always debate about the robustness of ANOVA in these cases, however this was addressed in the paper - non-parametric tests confirmed that there were no significant differences between Methylprednisolone and Gentamicin for vertigo outcomes ([1] Appendix, page 6).
Adrion also recommended adjustment for baseline differences, but a crucial strength of our study was adherence to the CONSORT 2010 guidelines for transparent reporting of trials [3], which states that “Although proper random assignment prevents selection bias, it does not guarantee that the groups are equivalent at baseline. Any differences in baseline characteristics are, however, the result of chance rather than bias. The study groups should be compared at baseline for important demographic and clinical characteristics so that readers can assess how similar they were…….Adjustment for variables because they differ significantly at baseline is likely to bias the estimated treatment effect.” Nevertheless, to satisfy Adrion and colleagues’ concerns and for the benefit of readers, we reanalysed our primary outcome data with ANCOVA using baseline vertigo attack frequency over 6 months as covariate. As with ANOVAs and non-parametric tests, the re-analysis showed no difference between drugs (F=.527 df=1,57 p=.471). In other words, performing the ANCOVA does not change our results nor add any further information for the reader.
Regarding (ii) the reason for the lack of power calculation for the primary outcome was clearly stated in our paper: “At the time of planning of our study, there were few published data on intratympanic gentamicin versus steroid treatment for Ménière’s disease”. Hence sample-size calculations were based on hearing outcomes where drug differences were better established [4]. However, we are now able to back-calculate our data. Depending on which outcome metric is chosen to resolve the small effects observed (vertigo attacks at 2 years, percentage reduction in vertigo attacks, absolute reduction in number of vertigo attacks, using intention to treat or per protocol), for conventional 80% power with p=.05 2-tailed the numbers of patients required is between 150 to over 400 per group, thus illustrating the minute differences, if any, for the primary outcome (vertigo).
Finally, the comment “the primary endpoint may be biased since it was assessed by retrospective face-to-face interviews instead of event-oriented or daily symptom diaries”, was also addressed in the paper. It would be unethical to recruit patients with refractory Meniere’s disease experiencing more than one attack per week (Table 1,[1]) and require that they fill up a diary for the next 6 months before receiving treatment. Further, all the validated vestibular questionnaires used showed no differences between Methylprednisolone and Gentamicin either. In the same vein, it would be unethical to give patients a placebo when gentamicin is more effective than placebo for vertigo control (for Cochrane Review, see [5]) and it should be emphasised that a comparison between Gentamicin and Placebo led to the early termination of a randomised, double-blind, controlled trial in 2014 [6]. In view of our data [1], we believe that the initial treatment choice between an ototoxic drug (Gentamicin) and one that it is not (Methylprednisolone), will be simplified for most patients and doctors.
References
[1] Patel M, Agarwal K, Arshad Q et al. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Meniere's disease: a randomised, double-blind, comparative effectiveness trial. Lancet 2016; 388(10061): 2753-62.
[2]. Mayor S. Steroid injections through the eardrum reduce dizziness in Meniere’s disease, study finds. BMJ 2016; 355:i6185.
[3] Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
[4] Sennaroglu L, Sennaroglu G, Gursel B et al. Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Meniere's disease. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery 2001; 125(5): 537-43.
[5] Pullens B, van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. Cochrane Database Syst Rev. 2011;(3):CD008234.
[6] Bremer HG, van Rooy I, Pullens B, et al. Intratympanic gentamicin treatment for Ménière's disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study. Trials 2014;15:328.
Competing Interests: None
Competing interests: No competing interests

Year2018
Output mediaOnline
PublisherBritish Medical Journal
Publication dates
Published28 Feb 2018
ISSN0959-8138
Web address (URL)http://www.bmj.com/content/355/bmj.i6185/rr-0

Related outputs

Long-term follow-up of intratympanic methylprednisolone versus gentamicin in patients with unilateral Menière’s disease
Harcourt, J.P., Lambert, A., Wong, P.Y., Patel, M., Agarwal, K., Golding, J.F. and Bronstein, A.M. 2019. Long-term follow-up of intratympanic methylprednisolone versus gentamicin in patients with unilateral Menière’s disease . Otology & Neurotology.

Reliability of functional outcome measures in adults with neurofibromatosis 1
Mullin, R.L., Golding, J.F., Smith, R., Williams, V., Thomas, M. and Ferner, R.E. 2018. Reliability of functional outcome measures in adults with neurofibromatosis 1. SAGE Open Medicine . 6, pp. 1-7.

The Effects of the Selective Muscarinic M3 Receptor Antagonist Darifenacin, and of Hyoscine (scopolamine), on Motion Sickness, Skin Conductance & Cognitive Function
Golding, J.F., Wesnes, K.A. and Leaker, B.R. 2018. The Effects of the Selective Muscarinic M3 Receptor Antagonist Darifenacin, and of Hyoscine (scopolamine), on Motion Sickness, Skin Conductance & Cognitive Function. British Journal of Clinical Pharmacology. 84 (7), pp. 1535-1543.

Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire
Ferner, R.E., Thomas, M., Mercer, G., Williams, V., Leschziner, G.D., Afridi, S.K. and Golding, J.F. 2017. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire. Health and Quality of Life Outcomes. 15, p. 34.

Predictors of clinical recovery from vestibular neuritis: a prospective study
Cousins, S., Kaski, D., Cutfield, N., Arshad, Q., Ahmad, H., Gresty, M.A., Seemungal, B.M., Golding, J.F. and Bronstein, A.M. 2017. Predictors of clinical recovery from vestibular neuritis: a prospective study. Annals of Clinical and Translational Neurology. 4 (5), pp. 340-346.

Meniere’s, Migraine & Motion Sickness
Golding, J.F. and Patel, M. 2017. Meniere’s, Migraine & Motion Sickness. Acta Oto‐Laryngologica. 137 (5), pp. 495-502.

Toxicity profile of bevacizumab in the UK Neurofibromatosis Type 2 cohort
Morris, K.A., Golding, J.F., Blesing, C., Evans, D.G., Ferner, R.E., Foweraker, K., Halliday, D., Jena, R., McBain, C., McCabe, M.G., Swampillai, A., Warner, N., Wilson, S., Parry, A. and Afridi, S. 2017. Toxicity profile of bevacizumab in the UK Neurofibromatosis Type 2 cohort. Journal of Neuro-oncology . 131, pp. 117-124.

Motion Sickness Susceptibility and Management at Sea
Golding, J.F. 2017. Motion Sickness Susceptibility and Management at Sea. in: MacLachlan, M. (ed.) Maritime Psychology Springer. pp. 151-183

Embodied perspective-taking indicated by selective disruption from aberrant self motion
Gardner, M., Stent, C., Mohr, C. and Golding, J.F. 2017. Embodied perspective-taking indicated by selective disruption from aberrant self motion. Psychological Research. 81 (2), pp. 480-489.

Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial
Patel, M., Agarwal, K., Arshad, Q., Hariri, M., Rea, P., Seemungal, B.M., Golding, J.F., Harcourt, J.P. and Bronstein, A.M. 2016. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial. The Lancet. 338 (10061), p. 2753–2762.

Prevalence, Predictors & Prevention of Motion Sickness in Zero-G Parabolic Flights
Golding, J.F., Paillard, A.C., Normand, H., Besnard, S. and Denise, P. 2016. Prevalence, Predictors & Prevention of Motion Sickness in Zero-G Parabolic Flights. Aerospace Medicine & Human Performance . 88 (1), pp. 3-9.

Motion Sickness
Golding, J.F. 2016. Motion Sickness. in: Furman, J.M. and Lempert, T. (ed.) Handbook of Clinical Neurology, Volume 137 Elsevier. pp. 371-390

Invited lectures from a spatial orientation symposium in honor of Frederick Guedry, Day 2
Lawson, Ben D., Rupert, Angus H., Raj, Anil K., Parker, Jillian N., Thompson, Linda B. and Golding, J.F. 2016. Invited lectures from a spatial orientation symposium in honor of Frederick Guedry, Day 2 . USAARL, Fort Rucker, Al, USA USAARL, US Army, USA.

Biodynamic Hypothesis for the Frequency Tuning of Motion Sickness
Golding, J.F. 2016. Biodynamic Hypothesis for the Frequency Tuning of Motion Sickness. Aerospace Medicine & Human Performance. 87 (1), pp. 65-8.

Bevacizumab in NF2-related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation
Morris, K.A., Golding, J.F., Afridi, S., Blesing, C., Ferner, R.E., Halliday, D., Jena, R., Pretorius, P.M., Parry, A., Axon, P.R., Evans, D.G. and McCabe, M.G. 2016. Bevacizumab in NF2-related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice. 3 (4), pp. 281-289.

'Visual Vertigo’ and Motion Sickness
Bronstein, A., Golding, J.F. and Gresty, M. 2014. 'Visual Vertigo’ and Motion Sickness. in: Colombo, B. and Teggi, R. (ed.) Free Preview Vestibular Migraine and Related Syndromes Springer. pp. 91-104

Electrocortical therapy for motion sickness
Arshad, Q., Cerchiai, N., Goga, U., Nigmatullina, Y., Roberts, R.E., Casani, A.P., Golding, J.F., Gresty, M.A. and Bronstein, A.M. 2015. Electrocortical therapy for motion sickness. Neurology . 85 (14), pp. 1257-1259.

Pathophysiology and treatment of motion sickness
Golding, J.F. and Gresty, M.A. 2015. Pathophysiology and treatment of motion sickness. Current Opinion in Neurology. 28, pp. 83-88.

Motion sickness in migraine and vestibular disorders
Murdin, L., Chamberlain, F., Cheema, S., Arshad, Q., Gresty, M.A., Golding, J.F. and Bronstein, A.M. 2015. Motion sickness in migraine and vestibular disorders. Journal of Neurology, Neurosurgery and Psychiatry. 86 (5), pp. 585-587.

'Visual Vertigo’ and Motion Sickness
Bronstein, A.M., Golding, J.F. and Gresty, M.A. 2014. 'Visual Vertigo’ and Motion Sickness. in: Bruno Colombo and Teggi Roberto (ed.) Vestibular Migraine and Related Syndromes Switzerland Springer. pp. 91-104

Visual Dependency and Dizziness after Vestibular Neuritis
Cousins, S., Cutfield, N.J., Kaski, D., Palla, A., Seemungal, B.M., Golding, J.F., Staab, J.P. and Bronstein, A.M. 2014. Visual Dependency and Dizziness after Vestibular Neuritis. PLoS ONE.

Longitudinal evaluation of quality of life in 288 patients with Neurofibromatosis 2
Ferner, R.E., Shaw, A., Evans, D.G., McAleer, D., Halliday, D., Parry, A., Raymond F, L., Durie-Gair, J., Hanemann C, O., Hornigold, R., Axon, P.R. and Golding, J.F. 2014. Longitudinal evaluation of quality of life in 288 patients with Neurofibromatosis 2. Journal of Neurology. 26 (5), pp. 936-969.

Effects of prochlorperazine on vestibular ocular and perceptual responses: a randomised, double-blind, cross-over, placebo-controlled study
Patel, M., Nigmatullina, Y., Seemungal, B., Golding, J.F. and Bronstein, A.M. 2014. Effects of prochlorperazine on vestibular ocular and perceptual responses: a randomised, double-blind, cross-over, placebo-controlled study. Audiology and Neurotology. 19 (2), pp. 91-96.

Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults
Leschziner, G., Golding, J.F. and Ferner, R.E. 2013. Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults. American Journal of Medical Genetics Part A. 161 (6), pp. 1319-1322.

Motion sickness susceptibility in healthy subjects and vestibular patients: effects of gender, age and trait-anxiety
Paillard, A.C., Quarck, G., Paolino, F., Denise, P., Paolino, M., Golding, J.F. and Ghulyan-Bedikian, V. 2013. Motion sickness susceptibility in healthy subjects and vestibular patients: effects of gender, age and trait-anxiety. Journal of Vestibular Research. 23 (4), pp. 203-209.

Motion sickness and disorientation in vehicles
Golding, J.F. and Gresty, M.A. 2013. Motion sickness and disorientation in vehicles. in: Bronstein, A.M. (ed.) Oxford textbook of vertigo and imbalance Oxford Oxford University Press. pp. 293-306

Vestibular perception following acute unilateral vestibular lesions
Cousins, S., Kaski, D., Cutfield, N., Seemungal, B., Golding, J.F., Gresty, M.A., Glasauer, S. and Bronstein, A.M. 2013. Vestibular perception following acute unilateral vestibular lesions. PLoS ONE. 8 (5), p. e61862.

Vertigo and dizziness from environmental motion: visual vertigo, motion sickness, and drivers' disorientation
Bronstein, A.M., Golding, J.F. and Gresty, M.A. 2013. Vertigo and dizziness from environmental motion: visual vertigo, motion sickness, and drivers' disorientation. Seminars in Neurology. 33 (3), pp. 219-230.

The reliability of retrieval-induced forgetting
Potts, R., Law, R., Golding, J.F. and Groome, D.H. 2012. The reliability of retrieval-induced forgetting. European Psychologist. 17 (1), pp. 1-10.

The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2
Hornigold, R.E., Golding, J.F., Leschziner, G., Obholzer, R., Gleeson, M., Thomas, N., Walsh, D., Saeed, S. and Ferner, R.E. 2012. The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2. Journal of Neurological Surgery Part B: Skull Base. 73 (2), pp. 104-111.

Cognitive cues and visually induced motion sickness
Golding, J.F., Doolan, K., Achary, A., Tribak, M. and Gresty, M.A. 2012. Cognitive cues and visually induced motion sickness. Aviation, Space, and Environmental Medicine. 83 (5), pp. 477-482.

Respiratory vulnerability to vehicle buffeting
Sung, W.L., Kohli, N., Qu’adir, S., Golding, J.F., Bronstein, A.M. and Gresty, M.A. 2011. Respiratory vulnerability to vehicle buffeting. Clinical Autonomic Research. 21 (6), pp. 365-371.

Neurofibromatosis 2: a novel risk factor for hypertension?
Hornigold, R.E., Golding, J.F., Ferner, R.E. and Ferner, R.E. 2011. Neurofibromatosis 2: a novel risk factor for hypertension? American Journal of Medical Genetics Part A. 155 (7), pp. 1721-1722.

The effect of smoking nicotine tobacco versus smoking deprivation on motion sickness
Golding, J.F., Prosyanikova, O., Flynn, M. and Gresty, M.A. 2011. The effect of smoking nicotine tobacco versus smoking deprivation on motion sickness. Autonomic Neuroscience: Basic and Clinical. 160 (1-2), pp. 53-58.

Managing motion sickness
Murdin, L., Golding, J.F. and Bronstein, A.M. 2011. Managing motion sickness. BMJ.

Managing motion sickness
Murdin, L., Golding, J.F. and Bronstein, A.M. 2011. Managing motion sickness. British Medical Journal. 343, pp. 1213-1217.

Off vertical axis rotation motion sickness and field dependence
Cian, C., Ohlmann, T., Ceyte, H., Gresty, M.A. and Golding, J.F. 2011. Off vertical axis rotation motion sickness and field dependence. Aviation, Space, and Environmental Medicine. 82 (10), pp. 959-963.

Slalom walking with prism disorientation: impact on verbal and spatial tasks
Green, D.A., Zhu, J.L., Shah, A., Golding, J.F. and Gresty, M.A. 2010. Slalom walking with prism disorientation: impact on verbal and spatial tasks. Aviation, Space, and Environmental Medicine. 81 (8), pp. 728-734.

The social impact of dizziness in London and Siena
Bronstein, A.M., Golding, J.F., Gresty, M.A., Mandalà, M., Nuti, D., Shetye, A. and Silove, Y. 2010. The social impact of dizziness in London and Siena. Journal of Neurology. 257 (2), pp. 183-190.

Effect of temporal relationship between respiration and body motion on motion sickness
Denise, P., Vouriot, A., Normand, H., Golding, J.F. and Gresty, M.A. 2009. Effect of temporal relationship between respiration and body motion on motion sickness. Autonomic Neuroscience. 151 (2), pp. 142-146.

Off-vertical axis rotation of the visual field and nauseogenicity
Golding, J.F., Arun, S., Wortley, E., Wotton-Hamrioui, K., Cousins, S. and Gresty, M.A. 2009. Off-vertical axis rotation of the visual field and nauseogenicity. Aviation, Space, and Environmental Medicine. 80 (6), pp. 516-521.

Impact of vertigo and spatial disorientation on concurrent cognitive tasks
Gresty, M.A. and Golding, J.F. 2009. Impact of vertigo and spatial disorientation on concurrent cognitive tasks. Annals of the New York Academy of Sciences. 1164, pp. 263-267.

Adaptation of ventilation to 'buffeting' in vehicles
Green, D.A., Golding, J.F., Mandip, A., Faldon, M.C., Murphy, K.G., Bronstein, A.M. and Gresty, M.A. 2008. Adaptation of ventilation to 'buffeting' in vehicles. Clinical Autonomic Research. 18 (6), pp. 346-351.

Nauseogenicity of off-vertical axis rotation vs. equivalent visual motion
Bijveld, M.M.C., Bronstein, A.M., Golding, J.F. and Gresty, M.A. 2008. Nauseogenicity of off-vertical axis rotation vs. equivalent visual motion. Aviation, Space, and Environmental Medicine. 79 (7), pp. 661-665.

Cognitive impairment by spatial disorientation
Gresty, M.A., Golding, J.F., Le, H. and Nightingale, K. 2008. Cognitive impairment by spatial disorientation. Aviation, Space, and Environmental Medicine. 79 (2), pp. 105-111.

[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study
Ferner, R.E., Golding, J.F., Smith, M., Calonje, E., Jan, W., Sanjayanathan, V. and O'Doherty, M. 2008. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Annals of Oncology. 19 (2), pp. 390-394.

Cognitive performance in light current users and ex-users of ecstasy (MDMA) and controls
Golding, J.F., Groome, D.H., Rycroft, N. and Denton, Z. 2007. Cognitive performance in light current users and ex-users of ecstasy (MDMA) and controls. American Journal of Drug and Alcohol Abuse. 33 (2), pp. 301-307.

Genetic influences on motion sickness susceptibility in adult women: a classical twin study
Reavley, C.M., Golding, J.F., Cherkas, L.F., Spector, T.D. and MacGregor, A.J. 2006. Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviation, Space, and Environmental Medicine. 77 (11), pp. 1148-1152.

Motion sickness susceptibility
Golding, J.F. 2006. Motion sickness susceptibility. Autonomic Neuroscience. 129 (1-2), pp. 67-76.

Increasing cognitive load with increasing balance challenge: recipe for catastrophe
Barra, J., Bray, A., Vishal, S., Golding, J.F. and Gresty, M.A. 2006. Increasing cognitive load with increasing balance challenge: recipe for catastrophe. Experimental Brain Research. 174 (4), pp. 734-745.

Tachypnea and hypocapnia are induced by 'buffeting' in vehicles
Green, D.A., Bray, A., Golding, J.F., Bronstein, A.M. and Gresty, M.A. 2006. Tachypnea and hypocapnia are induced by 'buffeting' in vehicles. Clinical Autonomic Research. 16 (4), pp. 281-285.

Predicting individual differences in motion sickness susceptibility by questionnaire
Golding, J.F. 2006. Predicting individual differences in motion sickness susceptibility by questionnaire. Personality and Individual Differences. 41 (2), pp. 237-248.

Motion sickness susceptibility fluctuates through the menstrual cycle
Golding, J.F., Kadzere, P. and Gresty, M.A. 2005. Motion sickness susceptibility fluctuates through the menstrual cycle. Aviation, Space, and Environmental Medicine. 76 (10), pp. 970-973.

Can tamoxifen relieve motion sickness?
Gianni, M.C., Golding, J.F. and Goldhirsch, A. 2005. Can tamoxifen relieve motion sickness? Annals of Oncology. 16 (10), pp. 1713-1714.

Motion sickness
Golding, J.F. and Gresty, M.A. 2005. Motion sickness. Current Opinion in Neurology. 18 (1), pp. 29-34.

Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness
Yen Pik Sang, F., Billar, J., Gresty, M.A. and Golding, J.F. 2005. Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness. Perceptual and Motor Skills. 18 (1), pp. 29-34.

We are most aware of our place in the world when about to fall
Bray, A., Subanandan, A., Isableu, B., Ohlmann, T., Golding, J.F. and Gresty, M.A. 2004. We are most aware of our place in the world when about to fall. Current Biology. 14 (15), pp. R609-R610.

Perceived control, locus of control and preparatory information: effects on the perception of an acute pain stimulus
Williams, D., Golding, J.F., Phillips, K. and Towell, A. 2004. Perceived control, locus of control and preparatory information: effects on the perception of an acute pain stimulus. Personality and Individual Differences. 36 (7), pp. 1681-1691.

Suppression of sickness by controlled breathing during mildly nauseogenic motion
Yen Pik Sang, F., Golding, J.F. and Gresty, M.A. 2003. Suppression of sickness by controlled breathing during mildly nauseogenic motion. Aviation, Space, and Environmental Medicine. 74 (9), pp. 998-1002.

Effect of breathing supplemental oxygen on motion sickness in healthy adults
Ziavra, N., Yen Pik Sang, F., Golding, J.F., Bronstein, A.M. and Gresty, M.A. 2003. Effect of breathing supplemental oxygen on motion sickness in healthy adults. Mayo Clinic Proceedings. 78 (5), pp. 574-578.

Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape
Yen Pik Sang, F., Billar, J., Golding, J.F. and Gresty, M.A. 2003. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. Journal of Travel Medicine. 10 (2), pp. 108-112.

Impairment of spatial cognitive function with preservation of verbal performance during spatial disorientation
Gresty, M.A., Waters, S., Bray, A., Bunday, K. and Golding, J.F. 2003. Impairment of spatial cognitive function with preservation of verbal performance during spatial disorientation. Current Biology. 13 (21), pp. R829-R830.

Motion sickness and tilts of the inertial force environment: active suspension systems vs. active passengers
Golding, J.F., Bles, W., Bos, E., Haynes, T. and Gresty, M.A. 2003. Motion sickness and tilts of the inertial force environment: active suspension systems vs. active passengers. Aviation, Space, and Environmental Medicine. 74 (3), pp. 220-227.

Attentional demands of continuously monitoring orientation using vestibular information
Yardley, L., Papo, D., Bronstein, A.M., Gresty, M.A., Gardner, M., Lavie, N. and Luxon, L. 2002. Attentional demands of continuously monitoring orientation using vestibular information. Neuropsychologia. 40 (4), pp. 373-383.

Interference between postural control and mental task performance in patients with vestibular disorder and healthy controls
Yardley, L., Gardner, M., Bronstein, A.M., Davies, R., Buckwell, D. and Luxon, L. 2001. Interference between postural control and mental task performance in patients with vestibular disorder and healthy controls. Journal of Neurology, Neurosurgery and Psychiatry. 71 (1), pp. 48-52.

A motion sickness maximum around the 0.2 Hz frequency range of horizontal translational oscillation
Golding, J.F., Mueller, A.G. and Gresty, M.A. 2001. A motion sickness maximum around the 0.2 Hz frequency range of horizontal translational oscillation. Aviation, Space, and Environmental Medicine. 72 (3), pp. 188-192.

Permalink - https://westminsterresearch.westminster.ac.uk/item/q44w9/reply-to-adrion-et-al-on-patel-et-al-letter-to-the-editor-british-medical-journal


Share this
Tweet
Email